Amivantamab Plus Lazertinib for Osimertinib-Relapsed EGFR-Mutant Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Nat. Med. 2023 Sep 14;[EPub Ahead of Print], BC Cho, DW Kim, AI Spira, JE Gomez, EB Haura, SW Kim, RE Sanborn, EK Cho, KH Lee, A Minchom, JS Lee, JY Han, M Nagasaka, JK Sabari, SI Ou, P Lorenzini, JM Bauml, JC Curtin, A Roshak, G Gao, J Xie, M Thayu, RE Knoblauch, K ParkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.